{"id":730,"date":"2026-04-13T04:53:32","date_gmt":"2026-04-13T04:53:32","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&#038;p=730"},"modified":"2026-08-30T03:53:26","modified_gmt":"2026-08-30T03:53:26","slug":"lucitala-talazoparib-0-25mgx30-capsules","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/pt\/product\/lucitala-talazoparib-0-25mgx30-capsules\/","title":{"rendered":"LuciTala 0.25mg"},"content":{"rendered":"<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">HIGHLIGHTS OF PRESCRIBING INFORMATION<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">These highlights do not include all the information needed to use LuciTala safely and effectively. See full prescribing information for LuciTala.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; color: rgb(88, 88, 88); font-size: 17px;\">&nbsp;<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><strong><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">INDICATIONS AND USAGE<\/span><\/strong><strong><\/strong><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">LuciTala is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for:<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">Breast Cancer<\/span><\/p>\n<p style=\"margin-left: 21px; text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for LuciTala.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">HRR Gene-mutated mCRPC<\/span><span style=\"font-family: \u5b8b\u4f53;\">.<\/span><\/p>\n<p style=\"margin-left: 21px; text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;In combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><strong><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">DOSAGE AND ADMINISTRATION<\/span><\/strong><strong><\/strong><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">\u2022 Take LuciTala with or without food.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">Breast Cancer<\/span><\/p>\n<p style=\"margin-left: 21px; text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;The recommended dosage of LuciTala is 1 mg taken orally once daily until disease progression or unacceptable toxicity.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; text-indent: 7px; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;For adverse reactions, consider dosing interruption or dose reduction.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">HRR Gene-Mutated mCRPC<\/span><\/p>\n<p style=\"margin-left: 21px; text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;The recommended dosage of LuciTala is 0.5 mg taken orally once daily in combination with enzalutamide until disease progression or unacceptable toxicity.<\/span><\/p>\n<p style=\"margin-left: 21px; text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;Patients should also receive a gonadotropic-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><strong><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">DOSAGE FORMS AND STRENGTHS<\/span><\/strong><strong><\/strong><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">Capsules:&nbsp;<\/span><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\"><span style=\"font-family: &quot;Times New Roman&quot;;\">0.25mg<\/span>\u00d7<span style=\"font-family: &quot;Times New Roman&quot;;\">60 c<\/span><\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">apsules<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><strong><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">CONTRAINDICATIONS<\/span><\/strong><strong><\/strong><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53;\">None<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><strong><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">WARNINGS AND PRECAUTIONS<\/span><\/strong><strong><\/strong><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML): MDS\/AML occurred in patients exposed to LuciTala, and some cases were fatal. Monitor patients for hematological toxicity and discontinue if MDS\/AML is confirmed.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;Myelosuppression: LuciTala may affect hematopoiesis and can cause anemia, neutropenia, and\/or thrombocytopenia.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;Embryo-Fetal Toxicity: LuciTala can cause fetal harm. Advise of the potential risk to the fetus and to use effective contraception.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><strong><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">ADVERSE REACTIONS<\/span><\/strong><strong><\/strong><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">Most common adverse reactions (\u226520%) as a single agent, including&nbsp;<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">laboratory abnormalities, are:<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;Hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased, fatigue, glucose increased, aspartate aminotransferase increased, alkaline phosphatase increased, alanine aminotransferase increased, calcium decreased, nausea, headache, vomiting, alopecia, diarrhea, and decreased appetite.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">Most common adverse reactions (\u226510%) in combination with enzalutamide,&nbsp;<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">including laboratory abnormalities, are:<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;Hemoglobin decreased, neutrophils decreased, lymphocytes decreased, fatigue, platelets decreased, calcium decreased, nausea, decreased appetite, sodium decreased, phosphate decreased, fractures, magnesium decreased, dizziness, bilirubin increased, potassium decreased, and dysgeusia.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><strong><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">DRUG INTERACTIONS<\/span><\/strong><strong><\/strong><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px; text-wrap-mode: wrap;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">\u2022 P-gp Inhibitors: Reduce the dose when coadministered with certain P-gp inhibitors. Monitor for increased adverse reactions.<\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px; text-wrap-mode: wrap;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;BCRP Inhibitors: Monitor for potential increased adverse reactions.<\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px; text-wrap-mode: wrap;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><strong><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">USE IN SPECIFIC POPULATIONS<\/span><\/strong><strong><\/strong><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">\u2022<\/span><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">&nbsp;<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">Lactation: Advise women not to breastfeed.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: \u5b8b\u4f53; font-size: 14px;\">\u2022<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">Renal Impairment: Reduce the dose and monitor for increased adverse reactions for patients with moderate or severe renal impairment.<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">&nbsp;<\/span><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><strong><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">Storage<\/span><\/strong><strong><\/strong><\/p>\n<p style=\"text-wrap-mode: wrap; line-height: 20px;\"><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">Store at 20<\/span><span style=\"font-family: Symbol; font-size: 14px;\">\u00b0<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">C to 25<\/span><span style=\"font-family: Symbol; font-size: 14px;\">\u00b0<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">C (68<\/span><span style=\"font-family: Symbol; font-size: 14px;\">\u00b0<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">F to 77<\/span><span style=\"font-family: Symbol; font-size: 14px;\">\u00b0<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">F), excursions permitted between 15<\/span><span style=\"font-family: Symbol; font-size: 14px;\">\u00b0<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">C and 30<\/span><span style=\"font-family: Symbol; font-size: 14px;\">\u00b0<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">C (59<\/span><span style=\"font-family: Symbol; font-size: 14px;\">\u00b0<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">F and 86<\/span><span style=\"font-family: Symbol; font-size: 14px;\">\u00b0<\/span><span style=\"font-family: &quot;Times New Roman&quot;; font-size: 14px;\">F) [see USP Controlled Room Temperature]. Protect from moisture.<\/span><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LuciTala is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for:  Breast Cancer<\/p>","protected":false},"featured_media":1810,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[46],"product_tag":[],"class_list":["post-730","product","type-product","status-publish","has-post-thumbnail","product_cat-ovarian-cancer","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product\/730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/comments?post=730"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/media\/1810"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/media?parent=730"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_brand?post=730"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_cat?post=730"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_tag?post=730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}